Quick Answer
Avalo Therapeutics, Inc. reported Long-Term Debt of $14.33 million for fiscal year 2018.
Avalo Therapeutics, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2018 | $14.33M | — |
| 2017 | $0.00 | — |
| 2016 | $0.00 | -100.0% |
| 2015 | $2.35M | -55.7% |
| 2014 | $5.31M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2019 | $14.25M | -0.7% | -0.2% |
| June 30, 2019 | $14.28M | -0.7% | -0.2% |
| March 31, 2019 | $14.30M | -2.0% | -0.2% |
| December 31, 2018 | $14.33M | — | -0.2% |
| September 30, 2018 | $14.35M | — | -0.2% |
| June 30, 2018 | $14.38M | — | -1.5% |
| March 31, 2018 | $14.59M | — | — |
| December 31, 2017 | $0.00 | — | -100.0% |
- Over the 2014–2018 period, Avalo Therapeutics, Inc.’s long-term debt has grown by 169.9% (from $5.31 million to $14.33 million).
- The most recent figure is from Avalo Therapeutics, Inc.’s fiscal year 2018 report (Form 10-K), filed with the SEC on March 18, 2019.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: